Join to View Full Profile
8901 Wisconsin AveWrnmmc, Dept Of Hem-Onc, America Bldg, 3rd FloorBethesda, MD 20889
Phone+1 301-319-2131
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Erin Larkins, MD is an oncologist in Bethesda, Maryland. She is currently licensed to practice medicine in Virginia. She is an Assistant Professor at Uniformed Services Hebert SOM.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Uniformed Services University of the Health Sciences F. Edward Hebert School of MedicineClass of 2000
Certifications & Licensure
VA State Medical License 2001 - 2026
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Most Common Symptomatic Adverse Reactions of Cancer Treatments From US Drug Labels (2015-2021) to Inform Selection of Patient-Reported Outcomes.Erica G Horodniceanu, Tejaswi Datla, Meena N Murugappan, Bindu Kanapuru, Laleh Amiri-Kordestani
Value in Health. 2025-01-01 - 7 citationsImpact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials.Jonathon Vallejo, Harpreet Singh, Erin Larkins, Nicole Drezner, Biagio Ricciuti
The Oncologist. 2024-05-03 - 15 citationsCorrelations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled anal...Bernardo Haddock Lobo Goulart, Sirisha L Mushti, Somak Chatterjee, Erin Larkins, Pallavi S Mishra-Kalyani
The Lancet. Oncology. 2024-04-01
Press Mentions
Dr. David Gerber, University of Texas Southwestern, and LUNGevity Foundation Publish Recommendations to Simplify and Harmonize Lung Cancer Clinical TrialsAugust 30th, 2022- Will FDA Mandate More Rigorous Design for Trials of Perioperative Therapies?August 8th, 2024
